HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors

Area of Science:

• Oncology
• Molecular Biology
• Medicinal Chemistry

Background:

• Current anti-cancer drugs often exhibit toxicity, limiting their clinical application.
• Targeting abnormal epigenetic factors, such as Histone Deacetylases (HDACs), offers a promising strategy for cancer treatment.
• There is a continuous need for potent and safe anticancer therapeutics with minimal adverse effects.

Purpose of the Study:

• To review the role of Histone Deacetylases (HDACs) in cancer malignancies.
• To discuss recent developments in the field of HDACs and their inhibitors.
• To provide an overview of clinically applied drugs, synthesis, SAR studies, and emerging classes of HDAC inhibitors.

Main Methods:

• Literature review focusing on HDACs in cancer.
• Analysis of developments in HDAC inhibitor research.
• Inclusion of data on clinically used drugs, synthesis, structure-activity relationships (SAR), and novel inhibitor classes.

Main Results:

• Histone Deacetylases (HDACs) play a significant role in the development and progression of various cancers.
• Numerous advancements have been made in identifying and developing HDAC inhibitors.
• Various classes of HDAC inhibitors, including synthetic, hybrid, and natural compounds, show potential for cancer therapy.

Conclusions:

• HDACs represent a critical target for novel anti-cancer drug development.
• Continued research into HDAC inhibitors is essential for creating safer and more effective cancer treatments.
• Understanding the SAR of HDAC inhibitors is key to designing potent and selective therapeutic agents.